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Abstract
Purpose: Xeroderma pigmentosum group D (XPD) codes for a DNA helicase involved in nucleotide excision repair that
removes platinum-induced DNA damage. Genetic polymorphisms of XPD may affect DNA repair capacity and lead to
individual differences in the outcome of patients after chemotherapy. This study aims to identify whether XPD
polymorphisms affect clinical efficacy among advanced non-small cell lung cancer (NSCLC) patients treated with platinum-
based chemotherapy.
Experimental Design: 353 stage III-IV NSCLC patients receiving platinum-based chemotherapy as the first-line treatment
were enrolled in this study. Four potentially functional XPD polymorphisms (Arg
156Arg, Asp
312Asn, Asp
711Asp and Lys
751Gln)
were genotyped by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry or PCR-based sequencing.
Results: Variant genotypes of XPD Asp
312Asn, Asp
711Asp and Lys
751Gln were significantly associated with poorer NSCLC
survival (P=0.006, 0.006, 0.014, respectively, by log-rank test). The most common haplotype GCA (in order of Asp
312Asn,
Asp
711Asp and Lys
751Gln) also exhibited significant risk effect on NSCLC survival (log-rank P=0.001). This effect was more
predominant for patients with stage IIIB disease (P=2.21610
24, log-rank test). Increased risks for variant haplotypes of XPD
were also observed among patients with performance status of 0–1 and patients with adenocarcinoma. However, no
significant associations were found between these polymorphisms, chemotherapy response and PFS.
Conclusions: Our study provides evidence for the predictive role of XPD Asp
312Asn, Asp
711Asp and Lys
751Gln polymorphisms/
haplotype on NSCLC prognosis in inoperable advanced NSCLC patients treated with platinum-based chemotherapy.
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Introduction
Non-small cell lung cancer (NSCLC) accounts for approxi-
mately 80% of primary lung cancers, with most of the patients
diagnosed at the advanced stage (stage III or IV) [1]. Although
chemotherapy involving platinum agents represents one of the
most common first-line treatments for these patients [2], the 5-year
survival rate remains less than 15% [3]. Clinical factors, such as
patient features (age and performance status) and disease
extension, roughly characterized by the stage, remained the major
determinations for prognosis of NSCLC [4]. However, variability
in outcomes has still been observed in patients with similar clinical
features. It seems that host inherited factors may have an
important role in the determination of treatment outcome for
NSCLC, which highlights the necessity of identifying genetic
markers for optimally individualized therapy [5].
Considering that platinum agents used for chemotherapy cause
DNA damage or cell death by activating the cell signaling
pathways [6], the host cellular DNA repair capacity possibly
influences the outcome of NSCLC patients after chemotherapy.
Previous studies have shown that suboptimal DNA repair capacity
within the tumor may lead to a decreased removal of DNA lesions,
and therefore increase the sensitivity to platinum-based chemo-
therapy, resulting in better clinical outcome [7–9].
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e33200Nucleotide excision repair (NER) is the major pathway for
repair of platinum-induced DNA cross-links in mammalian cells
[10]. The XPD gene encodes for an ATP-dependent helicase,
which mediates DNA unwinding for the initiation of NER [11].
Several studies have shown that XPD polymorphisms appear to
have an effect on DNA repair capacity possibly by altering the
function of protein product [12,13]. Common variants in the XPD
gene were found to be correlated with decreased cancer risk
[14,15]. And clinical and epidemiology evidences further indicate
that the XPD Lys
751Gln polymorphism was significantly associated
with chemotherapy effect [16,17]. However, for polymorphisms of
XPD Arg
156Arg and XPD Asp
711Asp, epidemiologic data on clinical
outcomes of NSCLC patients are still scarce. Therefore, the
prognostic importance of XPD polymorphisms remains unclear.
The XPD Asp
312Asn (rs1799793) and Lys
751Gln (rs13181)
polymorphisms are nonsynonymous single nucleotide polymor-
phisms (SNPs), resulting in a change to the amino acid sequence of
protein. Whereas, the Arg
156Arg (rs238406) and Asp
711Asp
(rs1052555) polymorphisms are both silent mutations. Our
previous study has shown that variant genotypes of XPD Arg
156Arg
were associated with an increased risk of serious hematologic
toxicity in Chinese Han population [18].
Based on these observations, we hypothesized that these four
potentially functional SNPs of XPD (at codons 156, 312, 711 and
751) may influence NSCLC prognosis. In this study, using DNA
samples obtained from a series of NSCLC patients, we assessed the
association between XPD polymorphisms and survival in advanced
NSCLC patients treated with platinum-based chemotherapy.
Materials and Methods
Patients recruitment and follow-up
The study design and subjects recruitment have been described
previously [18]. Patients with inoperable and histologically
confirmed stage III to IV NSCLC were consecutively recruited
between March, 2005, and August, 2008, from Shanghai Chest
Hospital in Shanghai, China. The eligible patients for this study
were at least 18 years old and were required to fulfill the following
criteria: the presence of a measurable lesion; Eastern Cooperative
Oncology Group performance status (ECOG PS) 0,2 (The
Eastern Cooperative Oncology Group Performance Status are
criteria used to assess how the disease affects daily life ability of
patients by grading it into 5 grades.) [19]; an absolute neutrophil
count (ANC) $1.5610
9 cells/L; platelets $100610
9 cells/L;
serum creatinine #1.56upper limit normal; Aspartate amino-
transferase (AST) and alanine aminotransferase (ALT) #1.56up-
per limit normal; estimated creatinine clearance $60 mL/min.
Patients were excluded if they had a prior history of malignancy
except for non-melanoma skin cancer, carcinoma in situ of the
uterine cervix, or an already cured tumor (.5-y disease-free
survival); previous chemotherapy, radiotherapy or surgery; active
congestive heart failure, cardiac arrhythmia, or recent (,3m o
before the date of treatment) myocardial infarction; any severe
mental disorder; infectious disease needing immunotherapy. A
written informed consent was provided by each patient. The study
was carried out with the approval of the Ethical Review
Committee of the hospital.
Before treatment, all the patients received evaluation including
complete medical history, health examination, scoring perfor-
mance status, routine clinical biochemistry tests, chest radiographs
and computed tomography of the chest and abdomen. Data on
demographic and clinical characteristics (including age, sex,
smoking status, and tumor histology) were obtained from clinical
medical records with review by the oncologists. For smoking
status, those who had smoked less than one cigarette per day and
less than 1 year in their lifetime were defined as non-smokers,
otherwise they were considered smokers. Information on survival
statistics were collected from several sources, including follow-up
calls, Social Security Death Index, and inpatient and outpatient
clinical medical records. All the investigators were blind to the
genetic polymorphism status of patients.
All the patients enrolled in this study were inoperable and
received the first-line platinum-based chemotherapy. The chemo-
therapeutic regimens were as follows: navelbine (25 mg/m
2)o n
day 1 and day 8 plus cisplatin (75 mg/m
2) or carboplatin (AUC 5)
on day 1, repeated every 3 week; gemicitabine (1,250 mg/m
2)o n
day 1 and 8 plus cisplatin (75 mg/m
2) or carboplatin (AUC 5) on
day 1, repeated every 3 weeks; Taxol (175 mg/m
2) plus cisplatin
(75 mg/m
2) or carboplatin (AUC 5) on day 1, repeated every 3
weeks; docetaxel (75 mg/m
2) plus cisplatin (75 mg/m
2) on day 1,
repeated every 3 weeks. Few patients were given other platinum-
based chemotherapy. All chemotherapy drugs were administered
intravenously, and all treatments were for two to six cycles. Patient
responses to the treatment were evaluated after first-line cycles of
chemotherapy by the Response Evaluation Criteria in Solid
Tumors (RECIST) guidelines version 1.0.
A total of 445 patients with advanced NSCLC participated in
this study, of which 353 had been completely followed-up. No
statistically significant difference was observed in the distribution
of demographic and clinical features between the patients included
in this study and those who did not (data not shown). As a result,
our final analysis was limited to these 353 patients.
SNP Genotyping
Blood samples were collected from each subject at the time of
recruitment, and the genomic DNA was extracted using QIAamp
DNA Maxi kit (Qiagen GmbH). The XPD Arg
156Arg, Asp
312Asn,
and Asp
711Asp polymorphisms were determined using the Seque-
nom MassARRAY iPLEX platform by the matrix-assisted laser
desorption/ionization time-of-flight mass spectrometer as previ-
ously described [18], and the Lys
751Gln was identified by PCR-
based sequencing. Primer sequences are available on request.
Overall, .98% of the genotypes were successfully determined for
all the SNPs. For quality control, 5% samples of the subjects were
randomly selected to re-genotype. All duplicate samples had a
genotype concordance of 100%.
Statistical analysis
Hardy-Weinberg equilibrium was tested for each SNP by
goodness-of-fit X
2 test. Pearson X
2 test (for categorical variables)
or student’s t-test (for continuous variables) was used to compare
the demographic and clinical characteristics. Patients achieving
complete response (CR) or partial response (PR) were defined as
‘‘responders’’, and patients with stable disease (SD) or progressive
disease were defined as ‘‘non-responders’’. Additional analyses
were done by grouping patients with CR, PR, and SD (defined as
‘‘patients with clinical benefit’’) versus those with PD (defined as
‘‘patients without clinical benefit’’).
Overall survival (OS) was calculated as the time to death from
the date of diagnosis. Progression-free survival (PFS) was
calculated as the time to progression or death without progression
from the date of diagnosis. Kaplan-Meier method was used to plot
PFS or OS curve, and the log-rank test was applied to compare the
distribution between groups. Multivariate Cox proportional
hazards models were used to estimated hazard ratios (HR) with
95% confidence intervals (95% CI). Clinical variables with log-
rank P,0.05 in univariate analysis were entered into multivariate
analysis. Due to the limited number of homozygous variant
XPD Polymorphisms and Clinical Outcomes
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312Asn, Asp
711Asp and Lys
751Gln polymorphisms were
modeled in a dominant model. For linkage disequilibrium (LD)
analysis, D9 and r
2 values for the genotyped SNPs were calculated
by Haploview software (http://www.broad.mit.edu/personal/
jcbarret/haplo/). The haplotype assessment was performed using
PHASE 2.0. Data were analyzed using SPSS, version 15.0 (SPSS,
Inc.). All P values were two sides, and statistical significance was set
at 0.05 levels.
To evaluate the chance of obtaining a false-positive association
due to multiple hypothesis testing, we used the Bayesian false-
discovery probability (BFDP) test [20] to calculate the probability
of no association with a moderate range of prior probabilities 0.1
and 0.05 on the presence of an association. The BFDP threshold
was set to 0.8, where a false non-discovery rate is four times as
costly as a false discovery.
Results
Patient characteristics and clinical outcomes
Demographic and clinic features of patients are presented in
Table 1. The median age was 57 (range, 32–80 years), and 246
(69.7%) patients were male. Among the subjects, 34 (9.6%) had
stage IIIA disease, 107 (30.3%) had stage IIIB, and 212 (60.1%)
had stage IV disease. Considering the histopathological type, 213
(60.3%) patients were diagnosed with adenocarcinoma, 75 (21.2%)
with squamous cell carcinoma, 12 (3.4%) with adenosquamocar-
cinoma, and 53 (15.0%) with other carcinoma.
Association between polymorphisms and clinical benefit
Genotype information is presented in Table 2. All the genotype
distributions were in accordance with Hardy-Weinberg equilibri-
um (P.0.05). Associations between polymorphisms and the
efficacy outcome of response rate and clinical benefit were
assessed using Pearson X
2 test and univariate logistic regression.
No SNPs were significant predictors of response rate or clinical
benefit overall (Table 2).
Association between XPD polymorphisms/haplotypes,
PFS and OS
Table 3 shows PFS and OS analysis data according to examined
polymorphisms. Overall median PFS was 7.3 months (95%
confidence interval, 6.52–8.14 months). Although Lys
751Gln
polymorphism showed marginal correlation with PFS, there were
no significant differences in PFS with respect to XPD genotypes.
Asp
312Asn, Asp
711Asp and Lys
751Gln polymorphisms showed
statistically significant associations with OS by log-rank test
(Table 3, Table 4 and Fig. 1). For XPD Asp
312Asn and Lys
751Gln
polymorphisms, the median survival time for patients with variant
genotypes (13 months, 15 months, respectively) was shorter than
that with wild-type homozygotes (MST, 19 months; log-rank
P=0.006, 0.014, respectively). These significances remained after
adjustment for performance status, stage and treatment regimens
(factors that were significantly associated with OS by log-rank test,
Table S1) in the Cox regression model (adjusted P=0.032, 0.034,
respectively) (Table 4). For Asp
711Asp polymorphism, the T-carrier
genotypes were associated with reduced survival compared to the
wild-type C/C genotype (14 months versus 19 months, log-rank
P=0.006). A marginally significant P value (0.053) was observed
after adjustment for clinical features (adjusted HR, 1.54; 95% CI,
1.00–2.38). No significant difference between Arg
156Arg and OS
was observed.
Pairwise linkage disequilibrium (LD) for the four SNPs was
presented in Table S2. A moderate LD was observed among
Asp
312Asn, Asp
711Asp and Lys
751Gln variants (0.42,D9,0.86). The
most common haplotype GCA (in order of Asp
312Asn, Asp
711Asp
and Lys
751Gln) was found to account for 90.5% of the studied
populations. The survival of patients with two copies of GCA
haplotype (wild type) was significantly longer than that of the
patients with zero to one copy (Table 4).
The BFDP values for the observed associations were calculated
at two levels of prior probabilities (0.1 and 0.05) (Table 4). At the
prior probability of 0.1, two SNPs (Asp
312Asn and Lys
751Gln) and
the haplotype remained noteworthy (BFDP#0.8).
Subgroup analysis of association between XPD
haplotypes and overall survival
The effects of Asp
312Asn haplotypes on NSCLC survival were
further evaluated by subgroups analysis of stage, histological type,
chemotherapy regimen and performance status (Table 5). A more
obvious evidence of association between the haplotypes and OS
was observed in stage IIIB patients (log-rank P=2.21610
24). The
variant haplotypes were associated with significantly decreased
survival (MST, 15 months; adjusted HR, 3.11; 95% CI, 1.66–
5.81), compared to the wild-type GCA haplotype (MST, 20
months). Statistically significant differences were also observed in
other subgroups (patients with ECOG performance status of 0–1
Table 1. Clinical characteristics of NSCLC patients.
Patients characteristics n (%)
Total no. of patients 353
Median age (range) 57 (32–80)
Gender
Male 246 (69.7)
Female 107 (30.3)
ECOG PS
0–1 336 (95.2)
2 17 (4.8)
TMN stage
IIIA 34 (9.6)
IIIB 107 (30.3)
IV 212 (60.1)
Histological type
Adenocarcinoma 213 (60.3)
Squamous cell 75 (21.2)
Adenosquamocarcinoma 12 (3.4)
Others
* 53 (15.0)
Smoking Status
Never smokers 154 (43.6)
Ever smokers 199 (56.4)
Chemotherapy regimens
Platinum- navelbine 187 (53.0)
Platinum-gemcitabine 54 (15.3)
Platinum- paclitaxel 73 (20.7)
Platinum- docetaxel 18 (5.1)
Other platinum combinations 20 (5.7)
NOTE: ECOG PS, Eastern Cooperative Oncology Group performance status;
TNM, tumor-node-metastasis.
*Others include mixed cell, neuroendocrine carcinoma, or undifferentiated
carcinoma.
doi:10.1371/journal.pone.0033200.t001
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type distribution did not differ significantly among NSCLC
patients, considering clinical factors as histology type, clinical
stage and PS (Table S3).
BFDP was conducted for the stratified analysis using the prior
probability of 0.1 and 0.05 (Table 5). The observed associations
remained noteworthy even at the prior probability of 0.05.
Discussion
This study evaluated whether common XPD polymorphisms
would influence clinical outcomes of Chinese NSCLC patients
treated with platinum-based chemotherapy. We found that the
variant genotypes and haplotypes of Asp
312Asn, Asp
711Asp and
Lys
751Gln polymorphisms significant contribute to shorter survival
time compared to corresponding wild-type homozygous geno-
types. After adjusting for clinical factors, the XPD haplotypes were
still significantly associated with OS, and this effect was more
predominant for patients with stage IIIB disease. Additionally, our
BFDP correction suggested that observed associations of those
SNPs in the main effect and subgroup analysis were probably not
due to false discoveries.
XPD is a member of a nine-subunit complex TFIIH that acts in
NER, and its helicase activity is required for the initiation of NER
process. Both in vivo and in vitro studies have indicated that
variations in the XPD gene may influence clinical benefits of the
Table 3. PFS and OS according to XPD polymorphisms.
Patients
Polymorphisms No. (%) Median PFS, mo (95% CI) Log-rank P Median OS, mo (95% CI) Log-rank P
Arg156Arg
C/C 85 (24.4) 7.5 (4.6–10.3) 0.691 18.0 (14.3–21.7) 0.759
C/A 194 (55.6) 7.7 (5.8–9.7) 19.0 (16.3–21.7)
A/A 70 (20.1) 7.0 (5.9–8.0) 17.0 (14.4–19.6)
Asp312Asn
G/G 308 (89.0) 7.4 (6.3–8.5) 0.790 19.0 (16.7–21.3) 0.006
A/G+A/A 38 (11.0) 7.3 (4.9–9.8) 13.0 (10.2–15.7)
Asp711Asp
C/C 319 (90.4) 7.5 (6.4–8.6) 0.245 19.0 (16.6–21.4) 0.006
C/T+T/T 34 (9.6) 6.2 (2.0–10.4) 14.0 (11.1–16.9)
Lys751Gln
A/A 304 (86.1) 7.5 (6.0–8.9) 0.062 19.0 (16.3–21.7) 0.014
A/C+C/C 43 (12.2) 5.3 (3.5–7.0) 15.0 (13.0–17.0)
NOTE: PFS: progression-free survival; OS: overall survival; CI: confidence interval.
doi:10.1371/journal.pone.0033200.t003
Table 2. XPD Polymorphisms and Tumor Response by Univariate Analysis.
Clinical Benefit (CR+PR+SD) (n=286) Response Rate (CR+PR) (n=62)
Polymorphisms No. (%) OR{ 95%CI{ P
{ No. (%) OR{ 95%CI{ P
{
Arg156Arg
C/C 73 (20.7) 1.00 Reference 0.775 18 (5.1) 1.00 Reference 0.682
C/A 154 (43.6) 1.12 0.52–2.40 31 (8.7) 1.31 0.68–2.51
A/A 57 (16.1) 0.82 0.30–2.24 13 (3.6) 1.07 0.48–2.39
Asp312Asn
G/G 251 (71.1) 1.00 Reference 0.597 52 (14.7) 1.00 Reference 0.305
A/G+A/A 30 (8.5) 1.29 0.50–3.29 9 (2.5) 0.66 0.29–1.48
Asp711Asp
C/C 258 (73.1) 1.00 Reference 0.849 54 (15.3) 1.00 Reference 0.339
C/T+T/T 28 (7.9) 0.90 0.30–2.70 8 (2.3) 0.66 0.28–1.55
Lys751Gln
A/A 249 (70.5) 1.00 Reference 0.651 52 (14.7) 1.00 Reference 0.440
A/C+C/C 32 (9.1) 1.24 0.49–3.17 9 (2.5) 0.73 0.32–1.63
NOTE: CR, complete response; PR, partial response; SD, stable disease; OR, odds ratio.
{Computed by Pearson Chi-Square test.
{estimated using univariate logistic regression.
doi:10.1371/journal.pone.0033200.t002
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751 have been investigated in several studies [12–17,21–27], but
no consensus has been reached. The genetic variations at codon
312 and 751 are nonsynonymous polymorphisms, resulting in a
change to the amino acid sequence of protein. In a previous study,
Seker et al. [28] reported that lymphoblastoid cells carrying the
variant A/A genotype at codon 312 displayed a higher apoptotic
response to UV compared with those carrying the wild-type
genotype. Besides, several studies suggested that XPD 751-Gln
substitutions might produce significant conformational change to
the protein [25], leading to a low number of chromatid aberration
and decreased risk of suboptimal DNA repair [12]. Our results
were consistent with previous experimental and epidemiologic
findings that the variant genotypes were associated with more
efficient DNA repair capacity in human tissues, resulting in
decreased effect of cytotoxic chemotherapy. The Asp711Asp
polymorphism is a common silent substitution. The Asp711Asp
and Lys751Gln polymorphisms were in strong LD (D9=0.86), and
the exact function of Asp711Asp has not been elucidated yet. It
could possibly affect the stability of mRNA or influence the rate of
translation by converting a high usage codon to a low usage one.
Alternatively, it was biologically plausible that this correlation was
mediated by linkage disequilibrium with Lys751Gln or some other
potentially functional SNPs.
In our analysis, a more significant association was found with
the reduced survival in the haplotype analysis. This effect was still
significant after the adjustment for clinical factors (adjusted
P=0.008). The cumulative effect of XPD haplotype might be
Table 4. Polymorphisms associated with OS.
Median OS, Multivariate analysis
BFDP
prior
Polymorphisms mo (95% CI) Log-rank P Adjusted Hazard Ratio (95% CI)
{ P
{ 0.1 0.05
Asp312Asn
G/G 19.0 (16.7–21.3) 0.006 1.00 (reference) 0.032 0.77 0.88
A/G+A/A 13.0 (10.2–15.7) 1.55 (1.04–2.32)
Asp711Asp
C/C 19.0 (16.6–21.4) 0.006 1.00 (reference) 0.053 0.82 0.90
C/T+T/T 14.0 (11.1–16.9) 1.54 (1.00–2.38)
Lys751Gln
A/A 19.0 (16.3–21.7) 0.014 1.00 (reference) 0.034 0.77 0.88
A/C+C/C 15.0 (13.0–17.0) 1.54 (1.03–2.29)
XPD Haplotype
Haplotype GCA{
0 (Copy number, 2) 20.0 (16.8–23.2) 0.001 1.00 (reference) 0.008 0.50 0.68
1 (Copy number, 0–1) 15.0 (13.0–17.0) 1.59 (1.13–2.22)
NOTE: OS: overall survival; HR, hazard ratio; CI: confidence interval. BFDP: Bayesian false-discovery probability. Bold figures are those that remained noteworthy at the
0.8 BFDP level, suggesting true associations.
{Data were estimated from Multivariate Cox proportional hazards models, with adjustment of patient characteristics with P,0.05 in univariate analysis (performance
status, clinical stage, and type of treatment regimens).
{Haplotype was composed in order of Asp
312Asn, Asp
711Asp and Lys
751Gln; GCA was the most common haplotype.
doi:10.1371/journal.pone.0033200.t004
Figure 1. Kaplan–Meier curve of overall survival according to (A) XPD Asp
312Asn polymorphism and (B) XPD haplotype.
doi:10.1371/journal.pone.0033200.g001
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vitro/vivo studies based on the combination of these three loci
would help investigate the true biological mechanisms. Survival
difference of haplotype was more apparent in patients with stage
IIIB disease, which was highly in accordance with the study of
Gurubhagavatula et al [8]. One of the possible explanations is that
individuals with stage IV disease may have accumulated too many
mutations during the course of tumor growth, which may drive
treatment resistance and overwhelm any genetic change that may
have altered DNA repair capacity [8].
A recent meta-analysis pointed out that none of Asp
312Asn and
Lys
751Gln alone was significantly associated with OS in NSCLC
patients receiving platinum-based chemotherapy [30]. However,
when only Asians population were included, for Lys
751Gln polymor-
phism, only one study which included 108 patients was eligible for
final OS analysis; and for Asp
312Asn, no study was eligible for OS
analysis. As minor allele frequencies for those three polymorphisms
are considerably lower in Asian population than those in European
populations [31–33], adequate sample size was needed to boost the
power of this study. Therefore, examination of these SNPs in our
Chinese population will also help elucidate the mechanism of
interethnic differences in the outcome of patients after chemotherapy.
The statistically significant differences in OS for these SNPs
were also observed in patients with adenocarcinoma. Since
adenocarcinoma was the most common tumor type in Chinese
population and tended to show worse prognosis [34], this finding
was meaningful for effective prediction in a particular subgroup of
lung cancer patients. However, the XPD status in tumor cells
needed to be determined in tumor specimens. Although survival
outcome differed across XPD genotypes, response to therapy was
not different among those subgroups. It suggested that genetic
factors responsible for short-term efficacy were likely to be
different from those for OS [35].
Our study has several strengths. Compared to published studies,
a relatively large number of advanced NSCLC patients treated
with platinum-based chemotherapy as the first-line treatment were
enrolled in this study. The relatively homogeneous treatment
standard limited the potential confounding effect. Both patient
recruitment and data collection were carried out without the
knowledge of genetic status. In addition, the consistency of
subgroup analysis indicated that our findings were likely to be
biologically plausible.
Limitations of this work included its retrospective single-center
design and lack of other DNA repair genes. Until being confirmed
by multi-center prospective studies, results from this study should
not be over-interpreted. Since the incidence of EGFR mutation
was expected to be particularly high in East Asian population,
clinical trials examining XPD SNPs in NSCLC patients with
regard to EGFR mutation may help to clarify whether XPD
polymorphisms or haplotype could act as a predictive marker of
chemotherapy.
In conclusion, our results provided evidences for the predictive
role of XPD Asp
312Asn, Asp
711Asp and Lys
751Gln polymorphisms/
haplotype on NSCLC prognosis among NSCLC patients treated
with platinum-based chemotherapy, which suggested that these XPD
polymorphisms might be used in risk assessment for chemotherapy
effect prediction and individualized treatment optimization.
Supporting Information
Table S1 Comparison of overall survival according to
clinical characteristics of patients.
(DOC)
Table S2 Linkage disequilibrium (D9 and r
2) between
SNPs in XPD.
(DOC)
Table 5. Subgroup analysis of association between XPD haplotype and overall survival.
Haplotype GCA
{
0 (Copy number, 2) 1 (Copy number, 0–1) BFDP prior
Variables
Death/
Patients
MST
(months)
Death/
Patients
MST
(months) Log-rank P
Adjusted HR
(95% CI)
{ Adjusted P
{ 0.1 0.05
Total 340
TNM stage
III B 45/83 20.0 16/19 15.0 2.21610
24 3.11 (1.66–5.81) 3.8610
24 0.18 0.31
IV 104/166 17.0 29/38 13.0 0.085 1.39 (0.91–2.11) 0.131 / /
ECOG PS
0–1 153/265 20.0 45/58 15.0 2.35610
24 1.71 (1.22–2.40) 0.002 0.27 0.44
Chemotherapy regimens
Platinum–navelbine 91/154 21.0 18/25 15.0 0.216 1.41 (0.84–2.35) 0.194 / /
Platinum–gemcitabine 25/41 19.0 9/13 13.0 0.276 1.41 (0.63–3.16) 0.405 / /
Platinum–paclitaxel 31/55 18.0 11/14 18.0 0.176 1.60 (0.78–3.28) 0.198 / /
Histologic type
Adenocarcinoma 93/168 21.0 27/35 13.0 0.004 1.82 (1.17–2.85) 0.009 0.56 0.73
Squamous cell 37/61 19.0 10/12 18.0 0.283 1.24 (0.61–2.56) 0.553 / /
NOTE: ECOG PS, Eastern Cooperative Oncology Group performance status; TNM, tumor-node-metastasis; MST, median survival time; HR, hazards ratio; BFDP, Bayesian
false-discovery probability. Bold figures are those that remained noteworthy at the 0.8 BFDP level, suggesting true associations.
{Haplotype was composed in order of Asp
312Asn, Asp
711Asp and Lys
751Gln; GCA was the most common haplotype.
{Stratified tests was estimated by Multivariate Cox proportional hazards models, with adjustment of patient characteristics with P,0.05 in univariate analysis
(performance status, clinical stage, and type of treatment regimens).
doi:10.1371/journal.pone.0033200.t005
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